国家医疗保障局11月28日召开新闻发布会表示，70个新药被纳入国家医保药品目录，价格平均下降了60.7%。
Eight domestically-produced medicines that are seen as "major innovations" and have just hit the market in recent years are among the new additions to the catalog of medicines covered by national medical insurance system, said the National Healthcare Security Administration (NHSA) at a press conference.
国家医疗保障局在新闻发布会上表示，新增医保药品目录中包括8个近年来上市的国产重大创新药品。
国家医保药品目录（the catalog of medicines covered by national medical insurance system）是基本医疗保险（basic medical insurance）、工伤保险（work-related injury insurance）和生育保险（maternity insurance）基金支付药品费用的标准。目录所列西药部分（western medicine）、中成药部分（Chinese patent medicine）、协议期内谈判药品部分（catalogued medicine for renewal）和中药饮片部分（prepared ready-for-use traditional Chinese medicine）所列药品为基本医疗保险、工伤保险和生育保险基金准予支付费用的药品。
据悉，本轮国家医保目录调整谈判共涉及150个药品（the latest round of negotiations targeted 150 medicines），包括119个新增谈判药品（119 new additions to the negotiation）和31个续约谈判药品（31 existing ones for renewal）。119个新增谈判药品谈成70个，价格平均下降60.7%。其中，肿瘤、糖尿病等治疗用药的降幅平均在65%左右。31个续约药品谈成27个，价格平均下降26.4%。
国家医保局医药服务管理司司长熊先军说，
Some drugmakers have provided the lowest prices in the world for Chinese patients.
部分药品生产方给中国患者开出了全球最低价。
It is estimated that due to major price cuts resulting from negotiations and reimbursement from the national medical insurance system, the out-of-pocket amounts paid by patients will drop by between 80 and 95 percent.
保守估计，通过谈判降价和医保报销，总体上患者个人负担将降至原来的20%以下，个别药品降至5%以下。
The updated list now contains 2,709 drugs, 64 more than the original version released in 2017.
本次更新后的药品目录共收录药品2709个，与2017年版相比，净增64个。
新版药品目录将从2020年1月1日期实行。
- 药品采购政策
pharmaceutical procurement policies - 药品集中采购
pooled procurement of medicines - 医药分开
separate medical treatment and drug sales - 仿制药
generic medicines - 药品加成
medicine markups - 药品流通
medicine distribution
